Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Cognitive impairment in anxiety disorders

Full Text:


Anxiety disorders are an important biomedical problem due to the high prevalence and significant negative impact on the quality of life and the course of concomitant somatic and neurological diseases. Cognitive impairment (CI) is one of the most intensively studied aspects of pathological anxiety. Impairments in attention, executive functions, memory, cognitive deficit, as well as abnormal cognitions and metacognitions are identified in anxiety disorders. Moreover, the treatment of the latter with the most frequently used drugs (antidepressants, atypical antipsychotics, anticonvulsants, tranquilizers) does not lead to a significant improvement in cognitive functions, and often contributes to their worsening. In this connection, in addition to psychotherapy, cognitive function-improving agents play a large role in treating anxiety diseases associated with cognitive dysfunction. Ginkgo Biloba extract (EGb 761, Tanakan®) that positively affects cognitive functions, especially in the domains of memory, concentration and attention deserves special attention.

About the Authors

B. A. Volel
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia; Mental Health Research Center
Russian Federation

Department of Psychiatry and Psychosomatics, Faculty of General Medicine, 8, Trubetskaya St., Build. 2, Moscow 119991;

34, Kashirskoye Shosse, Moscow 115552

D. S. Petelin
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia; Mental Health Research Center
Russian Federation

Department of Psychiatry and Psychosomatics, Faculty of General Medicine, 8, Trubetskaya St., Build. 2, Moscow 119991;

34, Kashirskoye Shosse, Moscow 115552

R. V. Akhapkin
V.P. Serbsky Federal Medical Research Center of Psychiatry and Narcology, Ministry of Health of Russia
Russian Federation
23, Kropotkinsky Lane, Moscow 119034

A. A. Malyutina
Inernational Institute for Psychosomatic Health
Russian Federation
14, Neglinnaya St., Build. 1, Moscow 107031


1. Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015 Sep;17(3):327-35.

2. Kessler RC, Ruscio AM, Shear K, Wittchen HU. Epidemiology of anxiety disorders. Curr Top Behav Neurosci. 2010;2:21-35.

3. Kyrios M, Mouding R, Nedeljkovic M. Anxiety disorders – assessment and management in general practice. Aust Fam Physician. 2011 Jun;40(6):370-4.

4. Kessler R, Berglind P, Demler O. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005 Jun;62(6):593-602. doi: 10.1001/archpsyc.62. 6.593

5. Balhara Y. Diabetes and psychiatric disorders. Indian J Endocrinol Metab. 2011 Oct;15(4): 274-83. doi: 10.4103/2230-8210.85579.

6. Dissanayaka NNW, Lawson RA, Yarnall AJ, et al. Anxiety is associated with cognitive impairment in newly-diagnosed Parkinson's disease. Parkinsonism Relat Disord. 2017 Mar; 36:63-68. doi: 10.1016/j.parkreldis.2017.01.001. Epub 2017 Jan 4.

7. Sinoff G, Werner P. Anxiety disorder and accompanying subjective memory loss in the elderly as a predictor of future cognitive decline. Int J Geriatr Psychiatry. 2003 Oct;18(10):951-9. doi: 10.1002/gps.1004

8. Culpepper L. Generalized anxiety disorder and medical illness. J Clin Psychiatry. 2009;70 Suppl 2:20-4.

9. Tully P, Harrison N, Cheung P, et al. Anxiety and Cardiovascular Disease Risk: a Review. Curr Cardiol Rep. 2016;18(12):120. doi: 10.1007/s11886-016-0800-3

10. Barrera T, Norton P. Quality of life impairment in generalized anxiety disorder, social phobia, and panic disorder. J Anxiety Disord. 2009 Dec;23(8):1086-90. doi: 10.1016/j. janxdis.2009.07.011. Epub 2009 Jul 14.

11. Olatunji BO, Cisler JM, Tolin DF. Qualify of life in the anxiety disorders: a meta-analytic review. Clin Psychol Rev. 2007 Jun;27(5):572-81. doi: 10.1016/j.cpr.2007.01.015. Epub 2007 Feb 7.

12. Safren SA, Heimberg RG, Brown EG, et al. Quality of life in patients with social phobia. Depress Anxiety. 1996-1997;4(3):126-33. doi: 10.1002/(SICI)1520-6394(1996)4:33.0.CO;2-E

13. Millan M, Agid Y, Brune M, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov. 2012 Feb 1;11(2):141-68. doi: 10.1038/nrd3628.

14. Bandelow B, Baldwin D, Abelli M, et al. Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. World J Biol Psychiatry. 2017 Apr;18(3):162-214. doi: 10.1080/15622975. 2016.1190867. Epub 2016 Jul 15.

15. Ferreri F, Lapp L, Peretti C. Current research on cognitive aspects of anxiety disorders. Curr Opin Psychiatry. 2011 Jan;24(1):49-54. doi: 10.1097/YCO.0b013e32833f5585.

16. Mirza S, Ikram MA, Bos D, et al. Mild cognitive impairment and risk of depression and anxiety: A population-based study. Alzheimers Dement. 2017 Feb;13(2):130-139. doi: 10.1016/ j.jalz.2016.06.2361. Epub 2016 Aug 9.

17. Roiser J, Sahakian B. Hot and cold cognition in depression. CNS Spectr. 2013 Jun;18(3): 139-49. doi: 10.1017/S1092852913000072. Epub 2013 Mar 12.

18. Robinson O, Vytal K, Cornwell B, et al. The impact of anxiety upon cognition: perspectives from human threat of shock studies. Front Hum Neurosci. 2013 May 17;7:203. doi: 10.3389/ fnhum.2013.00203. eCollection 2013.

19. Cisler JM, Koster EH. Mechanisms of attentional biases towards threat in anxiety disorders: an integrative review. Clin Psychol Rev. 2010 Mar;30(2):203-16. doi: 10.1016/j.cpr.2009. 11.003. Epub 2009 Dec 14.

20. Волель БА. Навязчивые сомнения по контрасту. Журнал неврологии и психиатрии им. С.С. Корсакова. 2002;102(9):14-20. [Volel' BA. Obsessive doubts. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2002;102(9): 14-20. (In Russ.)].

21. Hindmarch I. Cognitive toxicity of pharmacotherapeutic agents used in social anxiety disorder. Int J Clin Pract. 2009 Jul;63(7):1085-94. doi: 10.1111/j.1742-1241.2009.02085.x.

22. Виноградова МГ, Тхостов АШ. Смысловая регуляция познавательной деятельности при истерическом расстройстве личности. Медицинская психология в России. Электронный научный журнал. 2010;2. http:// [Vinogradova MG, Tkhostov ASh. Semantic regulation of cognitive activity in the hysterical personality disorder. Meditsinskaya psikhologiya v Rossii. Elektronnyi nauchnyi zhurnal. 2010;2. http:// (In Russ.)].

23. Рыжова ИА. Когнитивный тренинг как психокоррекционный метод в психиатрии. Медицинская психология в России. Электронный научный журнал. 2017;5. [Ryzhova IA. Cognitive training as a method of psycho-correction in psychiatry. Meditsinskaya psikhologiya v Rossii. Elektronnyi nauchnyi zhurnal. 2017;5. (In Russ.)].

24. Холмогорова АБ. Интегративная психотерапия расстройств аффективного спектра. Москва: МЕДПРАКТИКА-М; 2011. 480 с. [Kholmogorova AB. Integrativnaya psikhoterapiya rasstroistv affektivnogo spectra [Integrative psychotherapy of affective spectrum disorders]. Moscow: MEDPRAKTIKA-M; 2011. 480 p.] [Kholmogorova A. B. Cognititve psychotherapy of affective disorders spectrum. 2011 – 480 p.]

25. Koen N, Stein D. Pharmacotherapy of anxiety disorders: a critical review. Dialogues Clin Neurosci. 2011;13(4):423-37.

26. Soholm B. Clinical improvement of memory and other cognitive functions by Ginkgo biloba: review of relevant literature. Adv Ther. 1998 Jan-Feb;15(1):54-65.

27. Grass-Kapanke B, Busmane A, Lasmanis A, et al. Effects of Ginkgo Biloba Special Extract EGb 761® in Very Mild Cognitive Impairment (vMCI). Neuroscience and Medicine. 2011;2(1): 48-56. doi: 10.4236/nm.2011.21007


For citations:

Volel B.A., Petelin D.S., Akhapkin R.V., Malyutina A.A. Cognitive impairment in anxiety disorders. Neurology, Neuropsychiatry, Psychosomatics. 2018;10(1):78-82. (In Russ.)

Views: 7604

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)